'Big Pharma' and Biotechnology Companies Boost U.S. Pulmonary Arterial Hypertension Markets.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c49159) has announced the addition of "U.S. Pulmonary Arterial Hypertension Markets" to their offering.

This research service covers the U.S. pulmonary arterial hypertension (PAH) markets and includes the four classes of PAH according to the New York Heart Association classification. The research service provides a market overview, competitive structure, market forecasts and market share analysis across these four segments.

Market Sectors

Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:

* Total U.S. PAH therapy

* Class I PAH therapy

* Class II PAH therapy

* Class III PAH therapy

* Class IV PAH therapy

"Big Pharma" and Biotechnology Companies Boost U.S. Pulmonary Arterial Hypertension Markets

The U.S. pulmonary arterial hypertension (PAH) markets have been growing due to the launch of new therapies as well as keen interest shown by "Big Pharma" and biotechnology companies. A small patient population notwithstanding, the market is expected to grow rapidly. "The development of a strong clinical pipeline with two major launches in 2007, and improvement in diagnosis rates are likely to drive market growth," says the analyst of this research service.

The number of treatment options available for this condition has grown considerably over the past few years with new therapies expected. The granting of orphan drug status has encouraged the development of drugs, which would have been cost-prohibitive and unprofitable under normal circumstances. "Big Pharma" companies are focusing on this therapeutic area despite the orphan drug status. With increasing awareness of the disease and introduction of better treatment options, diagnosis rates are expected to rise further.

In-licensing Deals and Mergers and Acquisitions Spur Strong Growth

An increase in in-licensing and M&A deals in the PAH markets is also leveraging growth. "The market has drawn interest from "Big Pharma" and biotechnology companies partly due to the high reimbursement rates and average revenue per patient," states the analyst. Therefore, companies are looking to enter into the market through mergers and acquisitions or licensing of clinical stage products.

The key competitive factors include efficacy, convenience of dosing, and side effect profiles of therapies. The progression of PAH is rapid and the mortality rates are extremely high with most patients surviving for less than 3-4 years post diagnosis. Hence, the efficacy of a drug to slow down the progression of the disease, coupled with convenience of dosing is the prime competitive factor.

For more information, visit http://www.researchandmarkets.com/reports/c49159